Intercept Pharmaceuticals Inc.

(ICPT) Trade

By |

Profile

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

Contact Information

Website: www.interceptpharma.com
Email: investors@interceptpharma.com
Main Phone: +1 646 747-1000
Address: 10 Hudson Yards
Address 2: 37th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10011

Issuer Information

Exchange: NGS
CEO: Mark Pruzanski
Employees: 483
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH. Intercept owns worldwide rights to OCA outside of China, where it has licensed out the product to Sumitomo Dainippon Pharma.

Contact Information

Website: www.interceptpharma.com
Email: investors@interceptpharma.com
Main Phone: +1 646 747-1000
Address: 10 Hudson Yards
Address 2: 37th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10011

Issuer Information

Exchange: NGS
CEO: Mark Pruzanski
Employees: 483
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 69.97 $ 0.69 (1.00%)
Last Price 69.97 Change $ 0.69 Change % 1.00 Tick N/A
Bid 69.92 Bid Size 600.00 Ask 70.02 Ask Size 500.00
Open 69.05 High 70.12 Low 68.63 Prev Close 69.28
Last Trade Volume 73,366 52 Wk Hi 133.74 52 Wk Low 68.20
Market Cap 2.3 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 32,545,693.00 EPS (TTM) -10.76 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 60
Number of Buys 4 29
Number of Sells 0 31
Net Activity 251170 451095
Last 10 Buys Shares
Mark Pruzanski 1,000
Daniel M. Bradbury 1,000
Keith Gottesdiener 1,000
Luca Benatti 1,000
Srinivas Akkaraju 1,000
Srinivas Akkaraju 1,000
Srinivas Akkaraju 1,000
Jonathan T. Silverstein 1,000
Srinivas Akkaraju 1,000
Last 10 Sell Shares
Richard Kim 1,000
Lisa Bright 1,000
Sandip S. Kapadia 1,000
Mark Pruzanski 1,000
Rachel McMinn 1,000
David Shapiro 1,000
David Shapiro 1,000
Lisa Bright 1,000
Lisa Bright 1,000
Lisa Bright 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 253 253 253 253
Low Target Price Estimate 57 57 57 57
Mean Target Price Estimate 116.23 116.23 116.23 116.23
Standard Deviation 60.13 60.13 60.13 60.13
Date of Most Recent Estimate 05/31/18 05/22/18 05/22/18 06/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 6 7 7
Moderate Buy 1 1 1 1
Hold 6 6 6 6
Moderate Sell 1 1 1 1
Strong Sell 0 0 1 1
Mean Rec. 2.14 2.14 2.21 2.21